Tissue-Specific Regulation of Type 1 Angiotensin II Receptor mRNA Levels in the Rat

Hypertension ◽  
1996 ◽  
Vol 28 (3) ◽  
pp. 403-408 ◽  
Author(s):  
Leonardo A. Sechi ◽  
Chandi A. Griffin ◽  
Gilberta Giacchetti ◽  
Jean-Pierre Valentin ◽  
Catherine Llorens-Cortes ◽  
...  
Diabetes ◽  
1992 ◽  
Vol 41 (9) ◽  
pp. 1113-1118 ◽  
Author(s):  
L. A. Sechi ◽  
C. A. Griffin ◽  
E. F. Grady ◽  
C. Grunfeld ◽  
J. E. Kalinyak ◽  
...  

Diabetes ◽  
1992 ◽  
Vol 41 (9) ◽  
pp. 1113-1118 ◽  
Author(s):  
L. A. Sechi ◽  
C. A. Griffin ◽  
E. F. Grady ◽  
C. Grunfeld ◽  
J. E. Kalinyak ◽  
...  

1999 ◽  
Vol 160 (3) ◽  
pp. 401-408 ◽  
Author(s):  
K Tamura ◽  
N Yokoyama ◽  
Y Sumida ◽  
T Fujita ◽  
E Chiba ◽  
...  

This study examined whether type 1 angiotensin II receptor (AT1) and angiotensin-converting enzyme (ACE) mRNAs are regulated during dietary salt loading in angiotensinogen gene-knockout (Atg-/-) mice which are genetically deficient in endogenous production of angiotensin II. Wild-type (Atg+/+) and Atg-/- mice were fed a normal-salt (0.3% NaCl) or a high-salt (4% NaCl) diet for 2 weeks. The mRNA levels were measured by Northern blot analysis. In Atg+/+ mice, concentrations of plasma angiotensin peptides were decreased by salt loading, whereas the treatment increased the brainstem, cardiac, pulmonary, renal cortex, gastric and intestinal AT1 mRNA levels. Salt loading also enhanced renal cortex ACE mRNA levels in Atg+/+ mice. Although plasma angiotensin peptides and urinary aldosterone excretion were not detected in Atg-/- mice, salt loading increased blood pressure in Atg-/- mice. In Atg-/- mice, pulmonary, renal cortex, gastric and intestinal AT1, and renal cortex and intestinal ACE mRNA levels were higher than those in Atg+/+ mice. However, salt loading upregulated AT1 mRNA expression only in the liver of Atg-/- mice, and the treatment did not affect ACE mRNA levels in Atg-/- mice. Furthermore, although the levels of ACE enzymatic activity showed the same trend with the ACE mRNA levels in the lung, renal cortex and intestine of both Atg-/- and Atg+/+ mice, the results of radioligand binding assay showed that cardiac expression of AT1 protein was regulated differently from AT1 mRNA expression both in Atg-/- and Atg+/+ mice. Thus, expression of AT1 and ACE is regulated by salt loading in a tissue-specific manner that appears to be mediated, at least partly, by a mechanism other than changes in the circulating or tissue levels of angiotensin peptides.


1994 ◽  
Vol 267 (6) ◽  
pp. E828-E836 ◽  
Author(s):  
S. Shanmugam ◽  
P. Corvol ◽  
J. M. Gasc

The two subtypes (AT1A and AT1B) of the type 1 (AT1) angiotensin II receptor mRNA were localized by in situ hybridization in rat fetal tissues from day 11 to 19 of gestation and in the young rat from day 0 to 10 postpartum, by use of 35S-labeled cRNA probes. Both subtype mRNAs were present in the kidney and in the adrenal gland. Organs such as liver, lung, heart, and undifferentiated mesenchymes expressed only AT1A mRNA. In contrast to the adult, only AT1A subtype was expressed during fetal and postnatal periods in the pituitary gland. Large blood vessels (e.g., aorta and cerebral arteries) expressed exclusively AT1A mRNA during fetal stages. The expression of each subtype appears to be differentially regulated, in a tissue- and age-specific way. This spatotemporal regulation of AT1A and AT1B expression suggests that angiotensin II could act as a differentiation factor during organogenesis in addition to its classical role as a regulator of the cardiovascular system.


2011 ◽  
Vol 7 (4) ◽  
pp. 254 ◽  
Author(s):  
Giuliano Tocci ◽  
Lorenzo Castello ◽  
Massimo Volpe ◽  
◽  
◽  
...  

The renin–angiotensin system (RAS) has a key role in the maintenance of cardiovascular homeostasis, and water and electrolyte metabolism in healthy subjects, as well as in several diseases including hypertension, left ventricular hypertrophy and dysfunction, coronary artery disease, renal disease and congestive heart failure. These conditions are all characterised by abnormal production and activity of angiotensin II, which represents the final effector of the RAS. Over the last few decades, accumulating evidence has demonstrated that antihypertensive therapy based on angiotensin II receptor blockers (ARBs) has a major role in the selective antagonism of the main pathological activities of angiotensin II. Significant efforts have been made to demonstrate that blocking the angiotensin II receptor type 1 (AT1) subtype receptors through ARB-based therapy results in proven benefits in different clinical settings. In this review, we discuss the main benefits of antihypertensive strategies based on ARBs in terms of their efficacy, safety and tolerability.


Hypertension ◽  
1997 ◽  
Vol 30 (3) ◽  
pp. 345-350 ◽  
Author(s):  
Donna H. Wang ◽  
Jingxin Qiu ◽  
Zhaoyong Hu ◽  
Yong Du

Sign in / Sign up

Export Citation Format

Share Document